Bruce Levine, CAR-T therapies, Carl June, Gilead, Kite, Tmunity Therapeutic, University of Pennsylvania
Kite completes acquisition of Tmunity
Press Release Feb 2023: - Kite, a Gilead Company (NASDAQ: GILD), today announced the completion of the previously announced transaction to acquire Tmunity Therapeutics (Tmunity), a clinical-stage, private biotech compan..
Brexucabtagene autoleucel, European Union, Gilead, Kite, Tecartus
Tecartus granted European marketing authorization for treatment of relapsed or refractory acute lymphoblastic leukemia
Sept 2022: The European Commission (EC) has authorized Kite's CAR T-cell therapy Tecartus® (brexucabtagene autoleucel) for the treatment of adult patients 26 years of age and older with relapsed or refractory (r/r) B-cell precurs..
Kite, Kymriah, Novartis, Yeskarta
CAR NK therapy has an effective rate of 73%
Immunotherapy in treatment of cancerCancer CAR-NK therapy has an effective rate of 73%, and is being recruited in domestic clinical trials.Immunotherapy has revolutionized the way cancer is treated. Cancer immunotherapy is divide..